14	ب	,c.7	
	, , 3	Please type a	plus sign (+) inside this b

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a yalid OMB control number.

substitute for form 1449A/PTO				
INFORMATION	DISCLOSURE			

STATEMENT BY APPLICANT

(use as many sheets as necessary)

5 1 of Sheet

Complete if Kn wn				
Application Number	09/829,031			
Filing Date	April 9, 2001			
First Named Inventor	Browning et al.			
Group Art Unit	1644			
Examiner Name	Bao Qun Li			
Attorney Docket Number	A063 US			

				U.S. PATENT DOCU	MENTS	
U.S. Patent Document				U.S. Patent Document	Date of Publication of	Pages, Columns, Lines, Where Relevant
Examiner Initials	Cite No.1	Number	(If known)	of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear
BOL	AA	~ 5,925,35		Browning et al.	7/20/99	•
·i	AB	5,225,5		Capon et al.	7/6/93	
	AC	4,816,56	57	Cabilly et al.	3/28/89	
	AD	4,544,54		Ryan et al.	10/1/85	
	AE	4,485,04	45	Regen	11/27/84	
V	AF	3,773,9	19	Boswell et al.	11/20/73	
						. <u> </u>
						``
						· · · · · · · · · · · · · · · · · · ·
	1					
		2				
						· · · ·

					FORE	IGN PATENT DOCUMENT	S		
Exam Initial		Cite No.1	Office ³	Foreign Patent Docum		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
B	α	' BA		DE 32 18 121	Al	Leskovar	11/17/83		
		ВВ		EP 0 058 481	Bi	Hutchinson	10/01/86		
H		ВС	1 -	WO 96/22788	Al	Browning et al	08/01/96		丄
		BĐ		WO 94/13808	A2	Browning et al	06/23/94		┦
	1	BÆ		WO 94/04679	Al	Carter et al.	03/03/94		┵
	/	BF		WO 92/00329	A1	Browning et al.	01/09/92		+-
\vdash			++			-			士
-									\bot
┢		1							1

Examiner Signature	Maro Oun Li	Date Considered 04 (503

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

b	type	a plus	sign	(+)	inside this	→	—	
,	-34-	_ ,		٠.		-		ı

PTO/SB/08B (10-96)
be type a plus sign (+) inside this + + + + Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO	Comple	ete if Known	1
	Application Number	09/829,031	
INFORMATION DISCLOSURE	Filing Date	April 9, 2001	
STATEMENT BY APPLICANT	First Named Inventor	Browning et al.	
CIAILMENT DI ALI LICANT	Group Art Unit	1644	
(use as many sheets as necessary)	Examiner Name	Bao Qun Li	
Sheet 2 of 5	Attorney Docket Number	A063 US	

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	_				
Examiner Initials*	No.1 publisher, city and/or country where published.						
BOS	ca	Duzgunes et al., Journal of Cell. Biochem. Abst. Suppl. 16E 77 (1992); "Liposome Targeting to HIV-Infected Cells via Recombinant Soluble CD4 and CD4-IgG Immunoadhesin"					
2.	сђ	Abe, Yashuhito et al, Lymphokine and Cytokine Research, Vol. 11, No. 2, pp. 115-121 (1992); "Studies of Membrane-Associated and Soluble (Secreted) Lymphotoxin in Human Lymphokine-Activated T-Killer Cells in Vitro"					
	cc	Arulanandam, Antonio et al., J. Exp. Med, Vol. 177, pp. 1439-1450 (1993); "A Soluble Multimeric Recombinant CD2 Protein Identifies CD48 as a Low Affinity Ligand for Human CD2: Divergence of CD2 Ligands during the Evolution of Humans and Mice"					
	cd	Bethell, Delia et al., Journal of Infectious Diseases, Vol. 177, pp. 778-782 (1998); "Pathophysiologic and Prognostic Role of Cytokines in Dengue Hemorrhagic Fever"					
	ce ·	Beutler, B. et al., Science, Vol. 229, pp. 869-871 (1985); "Passive Immunization Against Cachectin/Tumor Necrosis Factor Protects Mice from Lethal Effect of Endotoxin"					
cf Bro		Browning, Jeffrey et al., Jour. of Immunology, Vol. 154, pp. 33-46 (1995); "Characterization of Surface Lymphotoxin Forms Use of Specific Monoclonal Antibodies and Soluble Receptors"					
	cg ·	Browning, Jeffrey et al., Cell, Vol. 72, pp. 847-856 (1993); "Lymphotoxin Beta, a Novel Member of the TNF Family that Forms a Heteromeric Complex with Lymphotoxin on the Cell Surface"					
	ch	Chaplin, D. et al., Curr. Opin. in Immunology, Vol. 10, pp. 289-297 (1998); "Cytokine regulation of secondary lymphoid organ development"					
lymphotoxin (LT-alpha) and a soluble d		Crowe, Paul et al., Jour. of Immunological Methods, Vol. 168, pp. 79-89 (1994); "Production of lymphotoxin (LT-alpha) and a soluble dimeric form of its receptor using the baculovirus expression system"					
	ci ,	Crowe, Paul et al., Science, Vol. 264, pp. 707-710 (1994); "A Lymphotoxin-beta-Specific Receptor"					
\	ck	Eppstein, Deborah et al, Proc. Natl Acad. Sci. USA, Vol. 82, pp. 3688-3692 (1985) Cell Biology; "Biological activity of a liposome-encapsulated murine interferon gamma is mediated by a cell membrane receptor"					

Examiner	M m M	Date	alth3
Signature	Doogun hi	Considered	04/12/12

^{*}EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with new communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/088 (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

09/829,031 **Application Number** April 9, 2001 **Filing Date** Jeffrey Browning et al. First Named Inventor 1644 **Group Art Unit** Bao Qun Li **Examiner Name Attorney Docket Number** A063

(use as many sheets as necessary) of Sheet

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s). publisher, city and/or country where published.	T²			
gac.	cl	Fagerstam, Lars et al., Handbook of Affinity Chromatography, Marcel Dekker, Inc., NY, pp. 229-252 (1993); Surface Plasmon Resonance Detection in Affinity Technologies.				
	cm	Force, Walker et al., Journal of Immunology, Vol 155, pp. 5280-5288 (1995); "Mouse Lymphotoxin-beta Receptor Molecular Genetics, Ligand Binding, and Expression"				
	cn ·	Hober, Didier et al., Am. Jour. Trop. Med. Hyg., Vol. 48, No. 3, pp. 324-331 (1993); "Serum Levels of Tumor Necrosis Factor-alpha (TNF-alpha), Interleukin-6 (IL-6), and interleukin-1 beta (IL-1 beta) in Dengue-Infected Patients"				
	co	Hwang, Karl et al., Proc. Natl. Acad. Sci. USA, Vol. 77, No. 7, pp. 4030-4034 (1980); "Hepatic uptake and degradation of unilamellar sphingomyelin/cholesterol liposomes: A kinetic study"				
	cp ,	Lacy, Mark et al., Adv. in Pediatric Infectious Diseases, Vol. 12, pp 21-53 (1997); "Viral Hemorrhagic Fevers"				
	cq	Lane, Peter et al., Eur. Journal of Immunology, Vol 22, pp. 2573-2578 (1992); "Activated human T cells express a ligand for the human B cell-associated antigen CD40 which participates in T cell-dependent activation of B lymphocytes"				
	cr	Langer, Robert, Chemtech, Vol 12, pp.98-105 (1982); "Controlled release of macromolecules"				
	CS 4	Langer, Robert et al., Jour. of Biomedical Materials Research, Vol 15, pp. 267-277 (1981); "Biocompatibility of polymeric delivery systems for macromolecules"				
	ct	Mackay, Fabienne et al., Jour. of Immunology, Vol 159, pp.3299-3310 (1997); "Cytotoxic Activities of Recombinant Soluble Murine Lymphtoxin-alpha and Lymphotoxin-alpha/beta Complexes"				
	cu	Mauri, Davide et al., Immunity, Vol 8, pp. 21-30 (1998); "LIGHT, a New Member of the TNF Superfamily, and Lymphotoxin alpha are Ligands for Herpesvirus Entry Mediator"				
V	cv	Miller, Glenn et al., Jour. Experimental Medicine, Vol 178, pp. 211-222 (1993); "Specific Interaction of Lymphocyte Function-associated Antigen 3 with CD2 can Inhibit T Cell Responses"				

Examiner	Duo Runt:	Date	04/15/03
Signature	Daro 119	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

4

Mig 0 3 2003

Sheet

PTC/SB/08B (10-96)

Please type a plus sign (+) inside this + + Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Provided the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of

5

Complete if Known		
Application Number	09/829,031	
Filing Date	9 April 2001	
First Named Inventor	Jeffrey L. Browning	
Group Art Unit	1644	
Examiner Name	Bao Qun Li	
Attorney Docket Number	A063 US	

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
Proci	cw •	Montgomery, Rebecca et al., Cell, Vol 87, pp.427-436 (1996); "Herpes Simplex Virus-1 Entry into Cells Mediated by a Novel Member of the TNF/NGF Receptor Family"	
	cx ·	Morrison, Sherie, Annual Review of Immunology, Vol. 10, pp.239-265 (1992); "IN VITRO ANTIBODIES: Strategies for Production and Application"	
	cý ,	Morrison, Sherie et al., Proc. Natl. Academy of Sciences USA, Vol. 81, pp. 6851-6855 (1984); "Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains"	
	cz	Pass, Harvey et al., Chest Surgery Clinics of North America, Vol. 5, No. 1, pp. 73-90 (1995); "The Macrophage, TNF, and other Cytokines"	
	cas	Queen, Cary et al., Proc. Natl. Academy of Sciences USA, Vol. 86, pp. 10029-10033 (1989); "A humanized antibody that binds to the interleukin 2 receptor"	
	cab	Roitt et al., Immunology, 3rd ed., pg. 4.8 (1993)	
	cac	Sheehan, Kathleen et al., Jour. of Immunology, Vol. 142, No. 11, pp. 3884-3893 (1989); "Generation and Characterization of Hamster Monoclonal Antibodies that Neutralize Murine Tumor Necrosis Factors"	
	cad	Sidman, Kenneth et al., Biopolymers, Vol. 22, pp. 547-556 (1983); "Controlled Release of Macromolecules and Pharmaceuticals from Synthetic Polypeptides Based on Glutamic Acid"	
	cae	Smith, Craig et al., Cell, Vol. 76, pp. 959-962 (1994); "The TNF Receptor Superfamily of Cellular and Viral Proteins: Activation, Costimulation, and Death"	
	caf	Traunecker, Andre et al., Nature, Vol. 339, pp. 68-70 (1989); "Highly efficient neutralization of HIV with recombinant CD4-immunoglobulin molecules"	
V	cag	Winter, Greg and Milstein Cesar, Nature, Vol 349, pp. 293-299 (1991); "Man-made antibodies"	

Examiner	Marguer 1:	Date Considered	04/14 B
Signature	Herogun	Considered	0-((,)

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw fine through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

				_
Please type	a plus sign	(+) inside th	- 🏎	1 4

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

5 of 5

Complete if Kn wn		
Application Number	09/829,031	
Filing Date	9 April 2001	
First Named Inventor	Jeffrey L. Browning	
Group Art Unit	1644	•
Examiner Name	Bao Qun Li	
Attorney Docket Number	A063 US	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s).	
BILL	cah	Wong, Grace et al., Nature, Vol 323, pp. 819-822 (1986); "Tumour necrosis factors alpha and beta inhibit virus replication and synergize with interferons"	
BOC.	cai	Zhou, M. et al., Biochemistry, Vol 32, pp. 8193-8198 (1993); "Real-Time Measurements of Kinetics of EGF Zhou, M. et al., Biochemistry, Vol 32, pp. 8193-8198 (1993) "Binding to Soluble EGF Receptor Monomers and Dimers Support the Dimerization Model for Receptor Activation"	
	_		

Examiner Signature Date Considered 0415 03





^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.